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NITROGEN dioxide  (NO2)  is  a  common  indoor  and
outdoor air pollutant whose role in the induction of
asthma is unclear. We investigated the effects of NO2
on  the  development  of  asthma-like  responses  to
allergenic  challenge  in  BALB/c  mice.  Ovalbumin
(OVA)-immunized mice were intranasally challenged
with OVA or saline solution just before starting a 3h
exposure to 5 or 20ppm NO2 or air. Twenty parts per
million  of  NO2 induced  a  significant  increase  of
bronchopulmonary  hyperreactivity  in  OVA-chal-
lenged  mice  and  of  permeability  according  to  the
fibronectin  content  of  the  bronchoalveolar  lavage
fluid (BALF) 24h after exposure, as compared with air
or 5ppm NO2. Eosinophilia (cell counts in the BALF
and eosinophil peroxidase of lung tissue) was detec-
ted  at  24  and  72h  with  similar  levels  for  air  and
20ppm NO2, whereas a marked reduction was unex-
pectedly observed for 5ppm NO2. At 24h, interleukin-
5  in  the  BALF  was  markedly  reduced  at  5ppm
compared  with  20ppm  NO2 and  was  also  more
intense for  20ppm  NO2 than  for the air group.  In
contrast to specific IgG1 titers, anti-OVA IgE titers and
interleukin-4 in the BALF were not affected by NO2
exposure. Irrespective of the concentration of NO2,
OVA-challenged  mice  did  not  develop  late  mucosal
metaplasia compared with those exposed to OVA-air.
These results indicate that a short exposure to NO2
can exacerbate or inhibit some features of the devel-
opment of allergic disease in mice and may depend
on the concentration of pollutant.
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Introduction
Asthma  is  an  allergic  respiratory  disease  that  has
captured a great deal of attention for several years.
One of its perplexing aspects is that its prevalence has
increased steadily during this century, doubling in the
past  20  years  in  most  industrialized  countries.1
Although  asthma is  familial  and  genome-wide  sear-
ches have identified genetic loci predisposing to the
disease,  it  is  unlikely  that  the  genetic  make-up  of
stable  populations  can  change  significantly  in  less
than one century. The probable cause of the epidemic
must  therefore  relate  to  the  environment.1 Several
recent studies have shown an association between air
pollution during episodes of smog and asthma exacer-
bations,  and  hospital visits  for asthma.2–4 Although
this finding does not address causality, it supports air
pollution  having  an  effect  on  acute  asthmatic  epi-
sodes. Current evidence also suggests that asthmatics
are more sensitive to the effects of air pollutants.5
Asthma is characterized by acute bronchoconstric-
tion, late bronchopulmonary hyperreactivity, pulmo-
nary  eosinophilic  inflammation,  excessive  mucus
production and increased serum IgE titers,6 induced
by  a  variety  of  stimuli.  Its  pathology  seems  to  be
directly  linked  to  the  presence  in  the  airways  of
eosinophils and of T helper 2  (Th2)  CD4+ lympho-
cytes,7,8 which produce  interleukin  (IL)-4  and  IL-5.
These Th2 cytokines are said to play a central role in
the  initiation  and  perpetuation  of  asthma.9 IL-5
regulates the growth, differentiation and activation of
eosinophils and provides an essential signal for their
recruitment  to  the  lungs  during  allergic  inflamma-
tion.10 IL-4 induces the differential development of T
helper  0  cells  into  Th2  cells,11 and  stimulates  B
lymphocytes to produce IgE.12
Nitrogen  dioxide (NO2),  a  major potent  oxidant
pollutant,  is a well-known airway irritant.13 In con-
trast  to  other  pollutants,  NO2 is  a  widespread
contaminant of outdoor and of indoor environment.
Its indoor levels  can exceed those found outdoors,
and  are  provided  by  gas  cooking  appliances  and
tobacco smoke.14,15 By contrast, the main sources of
NO2 in outdoor air are motor vehicle emissions and
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high  concentrations  of  NO2 produce  changes  in
pulmonary  function,  increase  airway  responsive-
ness,16 and induce pulmonary edema.17 NO2 may also
cause release of inflammatory mediators, and induce
mast cell and lymphocyte infiltration.18Animal studies
have demonstrated that exposure to NO2 can increase
susceptibility  to  infection,  presumably  through  its
effect  on  lung  defense  mechanisms,  mucociliary
clearance,19 and  alveolar macrophage function.20,21
NO2 is  tissue  soluble,  with  unsaturated  bonds  in
membrane lipids of the airway and respiratory epithe-
lium,  as well lining  fluid, being its prime targets.22
Several studies have associated morbidity of asthma
with elevated concentrations of NO2.23,24 Based on
epidemiological  studies,  it  has  been  suggested  that
NO2 increases  the  risk  for  exacerbations  of
asthma.25,26 Clinical observations have demonstrated
that exposure to NO2 correlates with exacerbations of
asthma and with the potentiation of airway reactivity
in asthmatics,27,28 in contrast to other studies, which
have failed to show an association between exposure
to NO2 and increased incidence of asthma.29 These
discrepancies show that the role of NO2 for allergic
disease is still unclear.
Since NO2 can increase the bronchial responsive-
ness  to  non-specific  stimuli  such  as  histamine  and
methacholine, it may hypothetically affect bronchial
responsiveness  and  other  features  of  asthma  to
inhaled  allergen  as  well. The  existence  of  such  an
interaction between NO2 and allergen resulting in an
augmented  allergic  reaction  has  been  sugges-
ted.24,27,30 In the present study, we investigated the
role  of  NO2 in  the  exacerbation  of  asthma  in  an
ovalbumin (OVA)-immunized mouse model. For that,
we studied whether a short-term exposure to low or
high  concentrations  of  NO2 can  potentiate  the
responses to allergenic challenge in (OVA)-immunized
mice, in order to define its possible adjuvant role in
the development of some features of asthma, such as
bronchopulmonary responsiveness, eosinophilic pul-
monary inflammation, production of Th2 cytokines,
and of specific IgE and mucus secretion.
Materials and methods
Animals
Male strain BALB/c mice (6–7 weeks of age, 23 ± 2g
body weight) purchased from the Centre d’Elevage R.
Janvier (Le Genest Saint-Isle, France) were housed in
the INERIS animal-care unit, a facility accredited by
the  Departmental  Direction  of Veterinary  Services.
The  animals  had  free  access  to  conventional  labo-
ratory  feed  and  water.  Animals  were  handled  in
accordance with French State Council guidelines for
the  care  and  use  of  laboratory  animals  (Decree
number  87–849,  19  October  1987),  and  was
approved by  the  Institutional Animal Care and  Use
Committee at the INERIS.
Antigen immunization and challenge
BALB/c mice were immunized by the subcutaneous
injection  of  10mg  of  OVA  (ICN  Biomedicals,  Inc.,
Aurora,  OH,  USA),  dispersed  in  1.6mg  of Al(OH)3
(Merk, Darmstadt, Germany) in 0.4ml of 0.9% NaCl
(saline) at days 0 and 7. At day 14, 1 week after the
second injection, immunized mice were intranasally
(i.n.) challenged with 10mg of OVA in 50ml of saline
for  about  10sec  under  anesthesia  by  intravenous
injection  of  ketamine  (35mg/kg  Imalgene®1000;
Merial, Lyon, France). Control mice were challenged
with the same volume of saline solution.
Exposure system
The whole body exposure system used to generate
NO2 and expose the animals was developed in the
laboratory  of  INERIS.  Unrestrained,  and  conscious
mice challenged with OVA or saline were individually
placed in a whole body glass chamber of  0.5l  and
were exposed to 5 or 20ppm NO2 or to air for 3h. In
each glass chamber, NO2 was delivered with a flow
rate of 5l/min, allowing one to have a renewal, and
was calibrated at the exact desired concentration in
synthetic air. The airflow of NO2 in each chamber was
monitored by a mass flow-meter during the period of
exposure. The relative pressure of the glass exposure
chamber was controlled by a manometer. Concentra-
tions  of  5  or  20ppm  of  NO2 were  obtained  from
cylinders of NO2 gas prepared and certified by the
supplier (Air Liquide, Le Blanc Mesnil, France).
Evaluation of bronchopulmonary
hyperreactivity
Bronchopulmonary  hyperreactivity  (BHR)  was  eva-
luated with a barometric plethysmography method.
Unrestrained, conscious mice were placed in a whole
body  plethysmographic  chamber  (EMKA Technolo-
gies,  Paris,  France)  that  measured  the  respiratory
waveforms. Animals were exposed to an aerosol of
methacholine  (Aldrich,  Milwaukee,  WI,  USA)  for
20sec at 0.1M delivered by an aerosolator. The index
of  airway  obstruction  was  expressed  as  enhanced
pause (Penh), in response to inhaled methacholine,31
calculated as: Penh = [Te / Tr – 1] ´ [Pef / Pif], where Te
is expiratory time, Tr is relaxation time, Pef is peak
expiratory flow and Pif is peak inspiratory flow. For
the graphic representation, each value was expressed
every minute and was calculated from the average of
three values of Penh recorded every 20sec. To simplify
the  interpretations,  the  area  under  the  curve  was
calculated for 15min. The graphics in terms of area
under the curve represent the quantitative expression
of BHR.
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bronchoalveolar lavage fluid
Mice were anesthetized by the intraperitoneal injec-
tion  of  urethane  (2g/kg  ethylcarbamate;  Sigma,  St
Louis,  MO,  USA)  and  the  abdominal  cavity  was
opened. Blood samples were collected from the post
vena cava, and serum was collected after centrifuga-
tion at 500 ´ g for 10min and stored at –20°C until
used. After exsanguination, the lungs were flushed via
the cannulated trachea with 4 ´ 0.5ml  of a sterile
phosphate-buffered saline (PBS) solution (phosphate
buffer 10 mM; pH 7.4). The total cell numbers were
counted  automatically  (Coulter  Counter  ZM,  Coul-
tronics,  Margency,  France).  Bronchoalveolar  lavage
fluid  (BALF)  was  cytocentrifuged  for  10min  (Cyto-
spin, Shandon, UK). Slides were stained with a May–
Gr¨ unwald–Giemsa-derived  method  (Diff  Quick;
Baxter Dade AG, Duedingen, Switzerland), and a total
of  200  cells  was counted for each sample by  light
microscopy, the percentage of each cell population
being calculated. The BALF was centrifuged for 10min
at 1850 ´ g, 4°C (Jouan, Saint Herblain, France) and
the supernatants were removed and stored at –20°C
until used.
Evaluation of lung eosinophil peroxidase
activity
To  quantify  the  lung  sequestration  of  eosinophils,
eosinophil peroxidase (EPO) activity in the lung was
evaluated in 96-well plates by a cytochemical enzyme
assay.32 Briefly,  lungs  were  removed  and  homoge-
nized  (Potter-Elvejhem  glass  homogenizer; Thomas,
Philadelphia, PA, USA) in 0.05M Tris-HCl buffer (pH 8)
containing 0.1% Triton X-100 solution. Lung homoge-
nates were centrifuged for 15min at 1600 ´ g, 4°C
(Bioblock  Scientific  2K15;  Sigma,  Illkirsh,  France).
EPO activity was measured in the supernatant, based
on the oxidation of o-phenylenediamine (Sigma) by
EPO in the presence of peroxide hydrogen. Incuba-
tions in duplicate were carried out in the absence or
presence  of  the  peroxidase  inhibitor  3-amino–
1,2,4-triazole  (Sigma).  Plates  were  read  with  an
automatic  microplate  at  490nm  and  results  are
expressed as optical density (OD).
Evaluation of cytokines
IL-4  in  the  BALF  was  evaluated  by  enzyme-linked
immunosorbent assay (ELISA). Briefly, 96-well plates
were coated with rat anti-mouse IL-4 (BVD4–1D11;
Perbio  Sciences,  Erembodegem-Aalst,  Belgium)  at
2mg/ml  diluted  in  0.1M carbonate buffer  (pH  8.2)
and incubated overnight at 4°C. Plates were washed
with  PBS/0.1%  Tween  20  and  blocked  with  PBS
containing 1% of bovine serum albumin overnight at
4°C. After washing, dilutions of recombinant murine
IL-4 (Perbio Sciences) (15.6–1000pg/ml) or samples
were applied overnight at 4°C. Then, biotinylated rat
anti-IL-4 antibody (BVD6–24G2; Perbio Sciences) was
added  at  0.5mg/ml  for  2h  at  4°C.  Plates  were
incubated  with  ExtrAvidin®  peroxidase  conjugate
(1:2000  to  each  well;  Sigma)  for  45min  at  room
temperature (RT). Plates were developed with tetra-
methylbenzidine  substrate  (Kiregaard  Perry  Labo-
ratories, MD, USA). The reaction was stopped with
2N sulfuric acid and the plates were read at 450nm
with an automatic microplate reader. The lower limit
of  detection  of  this  assay  is  , 10pg  of  IL-4/ml
sample.
IL-5 in the BALF was quantified using an immuno-
metric assay as described previously.33 Briefly, 96-well
plates were coated with 10mg/ml of rat anti-mouse IL-
5 (TRFK-4). To these were added dilutions of recombi-
nant IL-5 standard (7.6–1000pg/ml) or of the sample,
followed by an acetylcholinesterase-labelled rat anti-
mouse IL-5 antibody (TRFK-5) at 10 Ellman units/ml.
Absorbance was read at 405nm  with an automatic
microplate reader. The lower limit of detection of this
assay is , 5pg of IL-5/ml sample.
Evaluation of anti-OVA specific IgE and IgG1
The  specific  anti-OVA  specific  IgE  and  IgG1  in  the
serum were measured by ELISA. For the determina-
tion of specific IgE, 96-well plates were coated with
rat anti-mouse IgE (EM  95–3)  at 5mg/ml diluted in
0.5M  carbonate  buffer  (pH  9.6)  and  incubated
overnight at 4°C. The next day, plates were washed
with  PBS/0.1%  Tween  20  and  blocked  with  PBS
containing 1% of bovine serum albumin (BSA) for 2h
at RT. After blocking, plates were washed and serum
samples were added and incubated overnight at 4°C.
The  plates  were  then  washed  and  10mg/ml  of
biotinylated  OVA  was  added. The  remaining  steps
were performed exactly as described for IL-4.
For the evaluation of specific IgG1, 96-well plates
were coated with OVA (ICN Biomedicals) at 10mg/ml
diluted  in  0.1M  carbonate  buffer  (pH  8.2)  and
incubated overnight at 4°C. Plates were washed with
PBS/0.1% Tween 20 and blocked with PBS containing
1% of BSA for 1h at 37°C. After blocking and washing,
serum samples were added and incubated for 1h at
37°C. Plates were washed and incubated with Goat
anti-mouse  IgG1  alkaline  phosphatase  conjugate
(1:2000  to  each  well;  Caltag  Laboratories,  Burlin-
game,  CA,  USA)  for  1h  at  37°C. The  colorimetric
reaction  was  initiated  with  p-nitrophenylphosphate
(1mg/ml) (Sigma) at 37°C. Plates were read at 405nm
with an automatic microplate reader.
As  a  positive  control,  serum  pooled  from  OVA-
immunized and challenged mice was used. Data from
serum  samples  were  expressed  according  to  the
absorbance of positive control serum after subtract-
ing  the buffer-only  blank data from  both. An index
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OD buffer only) / (OD positive control – OD buffer
only).
Evaluation of fibronectin
To evaluate  the  intensity  of  exudation  through  the
airways, fibronectin in the BALF was measured by the
indirect  competitive  ELISA  method  described  by
Rennard et al.34 Briefly, 96-well  plates were coated
with  murine  fibronectin  (Anawa, Wangen,  Switzer-
land) at 1mg/ml  diluted in 0.02M carbonate buffer
(pH 9.6) and incubated overnight at 4°C. In another
96-well plates, BALF samples and standard fibronectin
were  incubated  with  a  polyclonal  rabbit  anti-fibro-
nectin  antibody  (1:10000;  Anawa).  The  next  day,
plates  coated  with  fibronectin  were  washed  with
PBS/0.1% Tween 20 and blocked with PBS containing
1% of BSA for 2h at RT. Then, plates were rinsed with
PBS/0.1% Tween  20  and  100ml  of  antigen-antibody
were applied to the plates and incubated for 2h at RT.
After washing, the anti-fibronectin antibody that did
not bind with BALF fibronectin content was detected
with  a  biotinylated  secondary  anti-rabbit  antibody
(1:1500;  Amersham  Pharmacia  Biotech,  Orsay,
France)  and  incubated  for  2h  at  RT.  Plates  were
washed and incubated with ExtrAvidin® peroxidase
conjugate (1:20000 to each well; Sigma) for 45min at
RT. The remaining steps were performed exactly as
described for IL-4. The lower limit detection of this
assay is , 0.078 mg of fibronectin/ml sample.
Lung histology
After  exsanguination,  the  lungs  were  removed  and
fixed  by  intratracheal  instillation  with  10%  neutral
phosphate-buffer  formalin.  The  whole  lung  was
embedded  in  paraffin,  sectioned  at  a  thickness  of
5mm and stained with periodic acid Schiff to examine
mucus cells in the airway walls.
Statistical analysis
The results are expressed as mean ± standard error of
the  mean  (SEM).  Statistical  comparisons  between
groups were made using analysis of variance. Multiple
comparisons between all groups were performed by
Fisher’s least-significant difference test. p £  0.05 was
considered significant.
Results
To investigate the influence of NO2 on the responses
to the i.n. administration of OVA in immunized mice,
two  concentrations of  NO2 that are  relatively  high
compared  with  those  encountered  in  the  environ-
ment were used, since the actual amounts delivered
to  the  lung  are  quite  below  the  concentrations
inhaled.35,36 We have developed a murine model of
allergen-induced pulmonary inflammation sharing the
essential features of asthma, in which the two time
points of 24 and 72h after allergenic challenge allow
one to evaluate the parameters of the asthma pheno-
type. One week after the booster injection of antigen,
OVA-immunized mice were challenged i.n. with 10mg
of OVA or saline just before the exposure to air or to
NO2 at 5 or 20ppm for 3h. The time points of 24 and
72h were studied after NO2 exposure. The peak of
BHR,  the  initial  phase  of  pulmonary  eosinophil
entrapment,  and  the  peak  of  production  of  Th2
cytokines were studied at 24h, whereas at 72h the
increase of pulmonary eosinophilic inflammation, the
late  mucosal  metaplasia  development  and  specific
immunoglobulins in serum were determined.
Bronchopulmonary responsiveness to
methacholine
At day 15 (i.e. 24h after the exposure to 20ppm NO2
or to air), immunized BALB/c mice challenged with
OVA  expressed  significant  BHR  as  compared  with
those exposed to 5ppm NO2 (Fig. 1). Mice challenged
with saline exposed to air or to NO2 did not develop
BHR.  In  OVA-challenged  mice  exposed  to  20ppm
B. Proust et al.
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FIG. 1. BHR is significantly augmented in immunized mice
exposed to 20ppm NO2. At day 14, immunized mice were
challenged i.n. with saline (h ) or OVA (j ) and were exposed
to 5 or 20ppm NO2 or to air for 3h. At days 15 (24h) and 17
(72h), BHR in response to methacholine was evaluated. The
graphic in terms of area under the curve (A.U.C) represents
the quantitative expression of BHR. Data are expressed as
the mean ± SEM. * p£  0.05, OVA-challenged mice compared
with their saline control; 
#p £  0.05, OVA-air group compared
with the NO2-OVA group (5 or 20ppm); 
m p £  0.05, 5ppm
NO2-OVA  group  compared  with  the  20ppm  NO2-OVA
group.NO2,  BHR  was significantly  increased as compared
with  those  exposed  to  air  and  to  5ppm  NO2. At
day  17,  72h  after  exposure,  OVA-challenged  mice
exposed  to  air  or  to  NO2 failed  to  develop  BHR
(Fig. 1).
Fibronectin exudation into the BALF
To evaluate the exudation through the airways, the
concentration  of  fibronectin  was  measured  in  the
BALF.  OVA-challenged  mice  exposed  to  air  or  to
20ppm NO2 released significantly increased amounts
of fibronectin in the BALF, whereas those levels were
very low in animals exposed to 5ppm NO2 (Fig. 2). In
contrast, exposure to 20ppm NO2 augmented by six-
to  seven-fold  the  fibronectin  concentrations in  the
BALF of OVA-challenged mice after 24h, as compared
with the OVA-air group. NO2 at 20ppm also induced
a marked fibronectin exudation in saline-challenged
mice, as compared with the saline-air or saline-5ppm
NO2 groups. Seventy-two hours after exposure, BALF
fibronectin  content  persisted  in  saline-  or  OVA-
challenged mice exposed to 20ppm NO2. At this time
point, in OVA-challenged mice exposed to 5ppm NO2
or to air, the release of fibronectin was delayed, as
compared with mice exposed to 20ppm NO2 (Fig. 2).
Indeed, 24h after exposure to air or to 5ppm NO2,
no or low fibronectin was detected in the BALF of
OVA-challenged  mice.  But,  72h  after  exposure,
increased amounts  of  fibronectin were found,  con-
trary  to  mice  exposed  to  20ppm  NO2,  in  which
exudation started at 24h.
BALF cell infiltration and lung sequestration of
eosinophils
At 24h, neutrophil counts were increased in the BALF
of  OVA-challenged  mice exposed to  air or to NO2.
These counts were found significantly increased and
Effects of inhaled NO2 on allergic mice
Mediators of Inflammation · Vol 11 · 2002 255
FIG. 2. BALF fibronectin content after short exposure to NO2.
At day 14, immunized mice were challenged i.n. with saline
(h ) or OVA (j ) and were exposed to 5 or 20ppm NO2 or to air
for 3h. At days 15 (24h) and 17 (72h) after exposure, mice
were  sacrificed.  Fibronectin  levels  were  evaluated  in  the
BALF by ELISA. Data are expressed as the mean ± SEM. *p£
0.05,  OVA-challenged  mice  compared  with  their  saline
control; 
#p £  0.05, OVA-air group compared with the NO2-
OVA  group  (5  or  20ppm); 
d p £   0.05,  saline-air  group
compared with the NO2-saline group (5 or 20ppm); 
m p£  0.05,
5ppm NO2-OVA group compared with the 20ppm NO2-OVA
group; 
n p£  0.05, 5ppm NO2-saline group compared with the
20ppm NO2-saline group.
FIG. 3. BALF cell infiltration after exposures to NO2. At day
14, immunized mice were treated as in Fig. 2 (saline (h ) or
OVA (j )). Differential BALF cell counts and EPO of the lungs
were  evaluated.  (A)  Neutrophils,  (B)  eosinophils  and  (C)
eosinophil peroxidase. Data are expressed as  the mean ±
SEM. *p £  0.05, OVA-challenged mice compared with their
saline control; 
#p £  0.05, OVA-air group compared with the
NO2-OVA  group (5 or 20ppm); 
d p £  0.05, saline-air group
compared with the NO2-saline group (5 or 20ppm); 
m p£  0.05,
5ppm  NO2-saline  group  compared  with  the  20ppm  NO2-
saline group.in  OVA-challenged  mice  exposed  to  20ppm,  as
compared with  OVA-air  mice. The  increase  in  neu-
trophil counts in saline-challenged animals exposed to
20ppm NO2 was also significantly above that found in
saline-air or saline-5ppm NO2 mice (Fig. 3A). At 72h,
neutrophil counts were normalized in all groups of
mice (Fig. 3A). Eosinophils in the BALF were detected
at 24h and increased at 72h, with similar numbers in
OVA-challenged  mice  exposed  to  air  or  to  20ppm
NO2, as compared with those exposed to 5ppm NO2,
in which these counts were markedly reduced after
24 and 72h (Fig. 3B). The EPO activity in the lung
increased  significantly  in  OVA-challenged  mice
exposed to air at 24 and 72h. OVA-challenged mice
exposed to 5ppm NO2 showed a marked reduction of
EPO activity at 24 and 72h, as compared with the
OVA-air  group,  which  correlated with  the  reduced
eosinophil counts in the BALF. Significant reduction of
EPO activity was also noted in saline-challenged mice
exposed  to  5ppm  NO2,  as  compared  with  those
exposed  to  air. This  contrasts  with  results  in  mice
exposed to 20ppm NO2 or to air, in which EPO titers
were increased to similar levels (Fig. 3C).
Th2 cytokine production in the BALF
OVA-challenged  mice  exposed  to  air  or  to  NO2
released  IL-5  and  IL-4  in  the  BALF  at  24h.  In
connection with eosinophilia (cell counts and EPO in
the lungs),  the production of IL-5 in the BALF was
significantly  reduced  in  OVA-challenged  mice  24h
after exposure to 5ppm NO2, as compared with those
exposed to 20ppm NO2 or to air (Fig. 4A). However,
the  production  of  IL-5  was  increased  three-fold  in
OVA-challenged  mice  exposed  to  20ppm  NO2 as
compared  with  the  OVA-air  group,  and  was  aug-
mented by 10-fold as compared with those exposed
to 5ppm NO2 (Fig. 4A). By contrast, the production
of IL-4 in the BALF was increased to the same extent
in the three groups 24h after exposure (Fig. 4B). No
IL-4 nor IL-5 were detected in the BALF at the 72h
point (Fig. 4A,B).
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FIG. 4. BALF Th2 cytokine levels after exposures to NO2. At
day 14, immunized mice were treated as in Fig. 2 (saline (h )
or OVA (j )). Specific antibodies were evaluated in the serum
by  ELISA.  BALF  IL-4  and  IL-5  content  were  evaluated by
ELISA. (A) IL-5 and (B) IL-4. Data are expressed as the mean
± SEM. *p£  0.05, OVA-challenged mice compared with their
saline control; 
#p £  0.05, OVA-air group compared with the
NO2-OVA group (5 or 20ppm); 
m p £  0.05, 5ppm NO2-OVA
group compared with the 20ppm NO2-OVA group.
FIG. 5. Specific anti-OVA  IgE and IgG1 titers in the serum
after exposures to NO2. At day 14, immunized mice  were
treated  as  in  Fig.  2  (Saline  (h )  or  OVA  (j )).  Specific
antibodies were evaluated in the serum by ELISA. (A) IgE and
(B) IgG1. Data are expressed as the mean ± SEM. 
#p £  0.05,
OVA-air  group  compared  with  the  NO2-OVA  group  (5  or
20ppm); 
d p£  0.05, saline-air group compared with the NO2-
saline group (5 or 20ppm); 
m p£  0.05, 5ppm NO2-OVA group
compared with the 20ppm NO2-OVA group; 
n p£  0.05, 5ppm
NO2-saline  group  compared  with  the  20ppm  NO2-saline
group.Production of IgE and IgG1 anti-OVA antibody
in the serum
Saline- and OVA-challenged mice exposed to air or to
NO2 produced specific IgE and IgG1 detected in the
serum  24  and  72h  later.  The  anti-OVA  IgE  titers
increased  to  a  similar  extend  in  the  three  groups
after 72h (Fig. 5A), and both concentrations of NO2
failed to affect their production. Specific IgG1 titers
were  markedly  increased  as  compared  with  IgE,
without  significant  differences  between  saline  and
OVA-challenged  mice. Mice exposed to 5ppm  NO2
and  challenged  with  saline  or  OVA  showed  a  sig-
nificant  increase  of  IgG1  titers  as  compared  with
those  exposed  to  air  or  to  NO2 at  20ppm
(Fig. 5B).
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FIG. 6. Periodic acid Schiff (PAS)-stained histologic sections of lungs from allergic mice exposed to NO2. At day 14, immunized
mice were treated as in Fig. 2. Seventy hours after exposure, lungs were collected for histology. Goblet cells were stained with
PAS in lung sections. (A) Lung section of saline-challenged immunized mice exposed to air. (B) Lung section of OVA-challenged
immunized mice exposed to air. Note intense goblet cell hyperplasia (arrow). (C) Lung section of saline-challenged immunized
mice exposed to NO2 at 5ppm. (D) Lung section of OVA-challenged immunized mice exposed to NO2 at 5ppm. (E) Lung section of
saline-challenged immunized mice exposed to NO2 at 20ppm. (F) Lung section of OVA-challenged immunized mice exposed to
NO2 at 20ppm. Note the absence of goblet cell hyperplasia in saline-challenged mice exposed to air or NO2 in (A), (C) and (E), and
in OVA-challenged mice exposed to irrespective of the concentration of NO2 in (D) and (F) (final magnification, ´ 60).Histological analysis
As  expected,  the  bronchial  epithelium  of  saline-
challenged  immunized  mice  exposed  to  air  was
mucus free (Fig. 6A), under conditions where that of
immunized  and OVA-challenged mice was markedly
enriched in mucosal cells  (Fig.  6B).  Saline- or OVA-
challenged immunized mice exposed to NO2 at 5 or
20ppm  did  not  develop  mucosal  metaplasia  as
compared with OVA-challenged mice exposed to air
(Fig. 6D,F).
Discussion
Studies in asthmatics have shown that air pollutants
such  as  ozone,30 or  NO2 augment  the  allergic
responses.24,27,37,38 At high concentrations, NO2 is a
well-known airway irritant that can cause bronchial
constriction  in  normal  subjects,17,39 and  enhance
airway  responsiveness to  histamine40 or  methacho-
line16 in asthmatic patients, which are more sensitive
than healthy subjects. By contrast, few studies have
addressed to the interaction between NO2 and lung
allergy  in  experimental  animals. As  shown  here,  a
short-term  exposure  to  NO2 produces  contrasting
effects on the development of asthma-related respon-
ses  in  an  OVA-immunized  mouse  model,  which
depend on the dose of NO2. Thus, the high dose of
20ppm potentiated BHR, exudation and release of IL-
5 in the BALF after OVA challenge, under conditions
where the low dose of 5ppm failed to modify BHR,
and  reduced  significantly  pulmonary  eosinophilic
inflammation and the production of IL-5 in the BALF.
Since a single exposure to NO2 was used here, both
doses were relatively  high as compared with those
encountered in the environment. It has been repor-
ted, nevertheless, that the final amounts delivered to
the  lungs  are  quite  below  the  concentrations
inhaled.35,36
The potentiation of BHR by 20ppm NO2 in allergic
mice may be accounted for by an increased vascular/
epithelial permeability, facilitating the allergen avail-
ability  and  accelerating  the  inflammatory  process.
NO2 is  a  potent  tissue-soluble  oxidant,  which  can
induce pulmonary edema at high concentrations. In
our  experiments,  immunized  animals  treated  with
saline  and  exposed  to  20ppm  NO2 had  increased
titers of fibronectin in the BALF, which was used as an
indicator  of  permeability,  as  compared  with  the
saline-air  or  saline-5ppm  NO2 groups.  The  high
concentration of NO2 potentiated the effects of OVA,
since the fibronectin BALF content was significantly
increased  in  OVA-challenged  mice  exposed  to
20ppm, as compared with the OVA-air or OVA-5ppm
NO2 groups, and correlated with the increased BHR.
Even  though  BHR  disappeared  with  time,  the
increased permeability persisted 72h after exposure
to  20ppm,  whereas  a  more  delayed  increase  in
exudation  was  observed  in  OVA-challenged  mice
exposed  to  air  or  to  5ppm  of  NO2.  The  low
concentration of NO2 had an effect similar to that of
OVA  alone.  Since  our  mice  underwent  a  single
exposure  to  NO2,  it  is  possible  that  such  low
concentrations of NO2 become effective on repeated
exposures. In this context, the most probable mecha-
nism for NO2-induced increase in bronchial sensitivity
to inhaled allergens is the damage of epithelial cells
mediated by its oxidative activity, which may increase
the cell permeability to the allergen, thus increasing
its  delivered  dose,  as  occurs  in  cultured  human
epithelial cell monolayers exposed to NO2 over short
periods.41 This  would  account  for  the  augmented
fibronectin titers in the BALF, after its exudation from
the  plasma.  It  is  also  possible  that  NO2 acts  as  a
permissive agent, by allowing other factors to exacer-
bate asthma, or that underlying  factors such as the
intensity  of  allergy  or  inflammation  may  be  a  pre-
requisite for the expression of the detrimental effects
of the gas. Finally, NO2 can reduce the mucociliary
activity of the airways in vivo42 and in vitro,41 further
enhancing  the  accessibility  of  the  allergen  to  the
epithelial cells, owing to its decreased clearance from
the airways.
In our experiments, eosinophilia (cell counts and
EPO  lung  content)  and  IL-5  in  the  BALF  were
significantly reduced in OVA-challenged mice exposed
to 5ppm NO2. By contrast, 20ppm NO2 did not affect
eosinophilia, under conditions where the production
of  IL-5  in  the  BALF  was  significantly  increased  as
compared with the OVA-air group. Recently, Morris et
al.43 reported  that  the  exposure  to  0.7ppm  NO2
reduces eosinophilic inflammation in  allergic  mice,
but  the IL-5 levels  were not measured. The mecha-
nisms of the decreased eosinophilic inflammation and
IL-5 production in mice exposed to 5ppm NO2 are
unknown. They  may  result  from  alterations  in  the
regional deposition patterns of OVA and of NO2 in the
airways,  or  in  absorbance, pulmonary  clearance or
antioxidant  defenses.  Indeed,  NO2 has  a  low  so-
lubility,  and  is  poorly  absorbed  by  the  airway
mucosa.44 It is also a very reactive molecule whose
uptake in the respiratory system is extremely high.44
The use of mathematical dosimetry models suggests
that the uptake of NO2 between the trachea and the
respiratory zone occurs to a similar extent, and peaks
at the terminal bronchioles.44 It is also possible that
the biphasic effect of 5 and 20ppm NO2 may result
from  pharmacodynamic  alterations.  Some  studies
have  indeed  demonstrated  that  NO2 affects  lung
defense  mechanisms,  including  mucociliary  clear-
ance, alveolar macrophages (AM),  and  the immune
system.45The decreased OVA-induced IL-5 production
and eosinophilia after an exposure to 5ppm NO2 may
result  from  an  alteration of AM  function,  including
differences in antigen presentation by AM, or from a
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their surface, which may be hampered by exposure to
NO2. Indeed, Kineast et al.46 and Erroi et al.47 have
shown that NO2 exposure of LPS-stimulated human
AM  results  in  a  functional  impairment  of AM.  Fur-
thermore, Robison et al.21 demonstrated that expo-
sure rates to 0.5ppm NO2 for 0.5–10 days reduces the
arachidonate metabolism and superoxide production
in response to external stimuli. Thus, NO2 may reduce
the  capacity  of  AM  to  respond  to  immunologic
stimuli,  which might  explain  the decreased allergic
responses in animals exposed to 5ppm, in particular
eosinophilia and production of IL-5.
Airway  inflammation  is  accompanied  by  mucus
secretion, which contributes to airway obstruction. In
our experiments, irrespective of the concentration of
NO2, OVA-challenged mice did not develop mucosal
metaplasia, in contrast to those exposed to air, which
is probably  related to mucus  denaturation by  NO2-
induced  oxidation. The  mucus  layer  forms  a  pro-
tective barrier of the airways against the effects of
oxidants,  which  eliminates  and/or  scavenges  the
toxic components of NO2 prior to their diffusion into
the airway epithelium. The lipid content of the mucus
layer, in particular esterified unsaturated fatty acids,
constitutes the  primary  scavenging  oxidants.48 The
latter  demonstrated  that  the  phospholipids  of  the
mucus  layer  cannot  offer  a  significant  protection
against  inhaled  NO2 and  that  exposure  to  40ppm
NO2 in rats induces lipid peroxidation correlated with
the apparent lack of oxidant scavenging species in the
mucus lining the airways.
In summary, a short-term exposure to NO2 modifies
the asthma-like responses to allergenic challenge in
BALB/c mice with contrasting effects according to its
concentration. Despite the relatively high concentra-
tions of NO2 used in our investigation, as compared
with  those  encountered  in  the  environment,  this
study  provides  new  information  concerning  the
subtle  interactions  between  an  air  pollutant  and
allergic disease.
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